Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus | 18 | 2024 | 5891 | 1.970 |
Why?
|
Hypertension | 49 | 2023 | 8615 | 1.720 |
Why?
|
Diabetes Mellitus, Type 2 | 17 | 2023 | 12241 | 1.380 |
Why?
|
Sodium, Dietary | 10 | 2010 | 426 | 1.310 |
Why?
|
Veterans | 8 | 2024 | 2671 | 1.140 |
Why?
|
Diabetes Complications | 4 | 2023 | 1322 | 1.130 |
Why?
|
Antihypertensive Agents | 13 | 2020 | 2027 | 1.100 |
Why?
|
Blood Pressure | 32 | 2012 | 8541 | 0.980 |
Why?
|
Losartan | 7 | 2023 | 263 | 0.860 |
Why?
|
Angiotensin II | 12 | 2006 | 847 | 0.850 |
Why?
|
Renin-Angiotensin System | 7 | 2010 | 739 | 0.780 |
Why?
|
Blood Glucose | 9 | 2023 | 6430 | 0.670 |
Why?
|
Hypoglycemia | 3 | 2021 | 894 | 0.600 |
Why?
|
Diabetic Retinopathy | 5 | 2015 | 1299 | 0.590 |
Why?
|
Games, Experimental | 1 | 2017 | 32 | 0.590 |
Why?
|
Aldosterone | 16 | 2010 | 881 | 0.580 |
Why?
|
Diet, Sodium-Restricted | 8 | 2010 | 291 | 0.560 |
Why?
|
Blood Pressure Determination | 3 | 2010 | 646 | 0.540 |
Why?
|
Internet | 6 | 2017 | 3107 | 0.530 |
Why?
|
Sodium Chloride, Dietary | 3 | 2008 | 301 | 0.530 |
Why?
|
Life Expectancy | 2 | 2020 | 1249 | 0.520 |
Why?
|
Zona Glomerulosa | 6 | 1998 | 87 | 0.480 |
Why?
|
Health Policy | 2 | 2023 | 2698 | 0.440 |
Why?
|
Online Systems | 1 | 2014 | 182 | 0.430 |
Why?
|
Angiotensinogen | 3 | 2010 | 161 | 0.430 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2012 | 45 | 0.400 |
Why?
|
Receptors, Adrenergic, beta-2 | 2 | 2010 | 216 | 0.400 |
Why?
|
Electronic Mail | 3 | 2017 | 215 | 0.390 |
Why?
|
Eye Diseases | 2 | 2015 | 657 | 0.380 |
Why?
|
Video Games | 1 | 2014 | 202 | 0.380 |
Why?
|
Adrenergic Fibers | 1 | 2010 | 21 | 0.370 |
Why?
|
Hypoglycemic Agents | 7 | 2020 | 3108 | 0.370 |
Why?
|
Calcium Channel Blockers | 3 | 1998 | 692 | 0.360 |
Why?
|
Nutrigenomics | 1 | 2010 | 23 | 0.350 |
Why?
|
Adrenal Glands | 5 | 1998 | 557 | 0.350 |
Why?
|
Telemedicine | 5 | 2015 | 3107 | 0.340 |
Why?
|
Dementia | 1 | 2024 | 2729 | 0.330 |
Why?
|
Physical Examination | 2 | 2015 | 1262 | 0.330 |
Why?
|
Renin | 9 | 2010 | 648 | 0.320 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.320 |
Why?
|
Patient Compliance | 3 | 2010 | 2693 | 0.310 |
Why?
|
Potassium | 7 | 2010 | 1318 | 0.300 |
Why?
|
Office Visits | 2 | 2010 | 596 | 0.300 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2005 | 1517 | 0.300 |
Why?
|
Sympathetic Nervous System | 1 | 2010 | 521 | 0.290 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 623 | 0.280 |
Why?
|
Self Care | 1 | 2012 | 797 | 0.280 |
Why?
|
United States | 23 | 2024 | 73150 | 0.280 |
Why?
|
Humans | 109 | 2024 | 768393 | 0.280 |
Why?
|
Calcium | 10 | 2005 | 5794 | 0.280 |
Why?
|
Patient Education as Topic | 3 | 2009 | 2337 | 0.270 |
Why?
|
Appointments and Schedules | 1 | 2010 | 442 | 0.270 |
Why?
|
Diabetic Angiopathies | 3 | 2017 | 806 | 0.260 |
Why?
|
Sulfonylurea Compounds | 2 | 2020 | 220 | 0.260 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 829 | 0.250 |
Why?
|
Aged | 28 | 2024 | 171562 | 0.240 |
Why?
|
Male | 73 | 2024 | 364902 | 0.240 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7453 | 0.230 |
Why?
|
Hospitals, Veterans | 4 | 2010 | 395 | 0.230 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2001 | 1066 | 0.230 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2005 | 167 | 0.220 |
Why?
|
Nifedipine | 3 | 1998 | 220 | 0.220 |
Why?
|
Quality of Life | 2 | 2023 | 13503 | 0.220 |
Why?
|
Primary Health Care | 2 | 2010 | 4748 | 0.220 |
Why?
|
Female | 67 | 2024 | 397089 | 0.220 |
Why?
|
Diet | 6 | 2010 | 8090 | 0.220 |
Why?
|
Continuity of Patient Care | 1 | 2010 | 1076 | 0.220 |
Why?
|
Diastole | 6 | 2006 | 784 | 0.210 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 265 | 0.210 |
Why?
|
Renal Circulation | 3 | 2006 | 291 | 0.210 |
Why?
|
Erythrocytes | 2 | 2002 | 2421 | 0.210 |
Why?
|
Hyperaldosteronism | 1 | 2006 | 250 | 0.200 |
Why?
|
Protein Kinase C | 3 | 1998 | 1207 | 0.200 |
Why?
|
Middle Aged | 48 | 2023 | 223491 | 0.200 |
Why?
|
Prostate-Specific Antigen | 2 | 2010 | 2487 | 0.190 |
Why?
|
Overweight | 2 | 2023 | 2445 | 0.190 |
Why?
|
Computer-Assisted Instruction | 3 | 2012 | 364 | 0.180 |
Why?
|
Drug Utilization | 2 | 2010 | 1191 | 0.180 |
Why?
|
Myocardial Contraction | 1 | 2006 | 1527 | 0.180 |
Why?
|
Diltiazem | 2 | 1998 | 132 | 0.180 |
Why?
|
Guideline Adherence | 2 | 2010 | 2240 | 0.180 |
Why?
|
Antiporters | 1 | 2002 | 276 | 0.180 |
Why?
|
Hyperuricemia | 1 | 2023 | 223 | 0.180 |
Why?
|
Blood Volume | 2 | 1999 | 546 | 0.170 |
Why?
|
Insulin | 5 | 2020 | 6607 | 0.170 |
Why?
|
Medicare | 5 | 2022 | 6881 | 0.170 |
Why?
|
United States Department of Veterans Affairs | 6 | 2024 | 940 | 0.170 |
Why?
|
Pharmacists | 1 | 2002 | 261 | 0.170 |
Why?
|
Indomethacin | 1 | 2000 | 323 | 0.170 |
Why?
|
Captopril | 1 | 2000 | 262 | 0.170 |
Why?
|
Time Factors | 13 | 2024 | 40272 | 0.170 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2005 | 856 | 0.160 |
Why?
|
Parathyroid Hormone | 6 | 1999 | 1804 | 0.160 |
Why?
|
Patient-Centered Care | 2 | 2020 | 1447 | 0.160 |
Why?
|
Sodium | 9 | 2003 | 1594 | 0.160 |
Why?
|
Cross-Over Studies | 7 | 2007 | 2106 | 0.160 |
Why?
|
Isradipine | 1 | 1998 | 12 | 0.160 |
Why?
|
Treatment Outcome | 13 | 2023 | 65379 | 0.150 |
Why?
|
Hydrochlorothiazide | 1 | 1998 | 95 | 0.150 |
Why?
|
Polymorphism, Genetic | 2 | 2008 | 4250 | 0.150 |
Why?
|
Posture | 4 | 2005 | 956 | 0.150 |
Why?
|
Systole | 6 | 2005 | 937 | 0.150 |
Why?
|
Fructosamine | 1 | 2017 | 14 | 0.150 |
Why?
|
Computer Communication Networks | 1 | 1999 | 295 | 0.150 |
Why?
|
Metformin | 2 | 2016 | 911 | 0.150 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 3 | 2010 | 252 | 0.140 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59686 | 0.140 |
Why?
|
Prediabetic State | 1 | 2023 | 548 | 0.140 |
Why?
|
Retrospective Studies | 13 | 2023 | 81801 | 0.140 |
Why?
|
Mass Screening | 3 | 2007 | 5451 | 0.140 |
Why?
|
Internal Medicine | 1 | 2024 | 1057 | 0.140 |
Why?
|
Lymphocytes | 2 | 2002 | 2611 | 0.130 |
Why?
|
Gout | 1 | 2023 | 621 | 0.130 |
Why?
|
Prostatic Neoplasms | 2 | 2010 | 11221 | 0.130 |
Why?
|
Early Detection of Cancer | 1 | 2010 | 3236 | 0.130 |
Why?
|
Cytosol | 5 | 2005 | 886 | 0.130 |
Why?
|
New England | 2 | 2010 | 1058 | 0.130 |
Why?
|
Internship and Residency | 6 | 2024 | 5949 | 0.130 |
Why?
|
Insulin, Long-Acting | 1 | 2015 | 59 | 0.120 |
Why?
|
Prognosis | 5 | 2020 | 30022 | 0.120 |
Why?
|
Carrier Proteins | 3 | 1993 | 4936 | 0.110 |
Why?
|
Insulin Resistance | 2 | 2013 | 3981 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2000 | 849 | 0.110 |
Why?
|
Endocrinology | 1 | 2020 | 443 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2010 | 16028 | 0.110 |
Why?
|
Drug Substitution | 1 | 2016 | 291 | 0.110 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2014 | 146 | 0.110 |
Why?
|
Health Personnel | 1 | 2007 | 3380 | 0.110 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2006 | 251 | 0.110 |
Why?
|
Audiovisual Aids | 1 | 2014 | 99 | 0.110 |
Why?
|
Adult | 43 | 2023 | 223640 | 0.110 |
Why?
|
False Positive Reactions | 1 | 2015 | 962 | 0.100 |
Why?
|
Salicylates | 1 | 2013 | 128 | 0.100 |
Why?
|
Drug Approval | 1 | 1999 | 818 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 2276 | 0.100 |
Why?
|
Hydrogen-Ion Concentration | 4 | 1997 | 2488 | 0.100 |
Why?
|
Kinetics | 8 | 1998 | 6333 | 0.100 |
Why?
|
Photography | 1 | 2015 | 537 | 0.100 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2412 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2005 | 10377 | 0.100 |
Why?
|
Regression Analysis | 6 | 2010 | 6350 | 0.100 |
Why?
|
Catecholamines | 1 | 1992 | 390 | 0.100 |
Why?
|
Monitoring, Physiologic | 2 | 2012 | 1795 | 0.090 |
Why?
|
Thiazolidinediones | 1 | 2014 | 462 | 0.090 |
Why?
|
Hypocalcemia | 2 | 1991 | 203 | 0.090 |
Why?
|
Aging | 3 | 2020 | 8764 | 0.090 |
Why?
|
Hospitalization | 4 | 2021 | 10844 | 0.090 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3707 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1057 | 0.090 |
Why?
|
Exfoliation Syndrome | 1 | 2011 | 113 | 0.090 |
Why?
|
Obesity | 2 | 2023 | 13084 | 0.090 |
Why?
|
Patient Preference | 1 | 2017 | 947 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2014 | 696 | 0.080 |
Why?
|
Kallikreins | 1 | 2010 | 219 | 0.080 |
Why?
|
Sphygmomanometers | 1 | 2009 | 20 | 0.080 |
Why?
|
Fundus Oculi | 2 | 2008 | 560 | 0.080 |
Why?
|
Aorta | 2 | 2007 | 2046 | 0.080 |
Why?
|
Stethoscopes | 1 | 2009 | 30 | 0.080 |
Why?
|
Tetradecanoylphorbol Acetate | 4 | 2005 | 826 | 0.080 |
Why?
|
Educational Status | 2 | 2007 | 2518 | 0.080 |
Why?
|
Fruit | 4 | 2009 | 1164 | 0.080 |
Why?
|
Vegetables | 4 | 2009 | 1198 | 0.080 |
Why?
|
Citrates | 4 | 1994 | 134 | 0.080 |
Why?
|
Life Style | 4 | 2008 | 3929 | 0.080 |
Why?
|
Research Personnel | 2 | 2024 | 590 | 0.080 |
Why?
|
Cohort Studies | 5 | 2024 | 41795 | 0.070 |
Why?
|
Risk Assessment | 3 | 2020 | 24318 | 0.070 |
Why?
|
Physicians | 2 | 2024 | 4614 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12558 | 0.070 |
Why?
|
Infusions, Intravenous | 6 | 1999 | 2226 | 0.070 |
Why?
|
Ophthalmoscopy | 1 | 2008 | 172 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 2 | 2007 | 1082 | 0.070 |
Why?
|
Fibrinolysis | 2 | 2002 | 331 | 0.070 |
Why?
|
Decision Making | 2 | 2018 | 3953 | 0.070 |
Why?
|
Hypercalcemia | 1 | 1989 | 423 | 0.070 |
Why?
|
Patient Selection | 4 | 2005 | 4266 | 0.070 |
Why?
|
Thiazepines | 1 | 2005 | 30 | 0.060 |
Why?
|
Diet, Atherogenic | 1 | 2005 | 92 | 0.060 |
Why?
|
Incidence | 1 | 2024 | 21544 | 0.060 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2006 | 169 | 0.060 |
Why?
|
Genotype | 3 | 2010 | 13042 | 0.060 |
Why?
|
Linkage Disequilibrium | 1 | 2010 | 1998 | 0.060 |
Why?
|
Kallidin | 1 | 2005 | 5 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10588 | 0.060 |
Why?
|
Cattle | 4 | 1998 | 3826 | 0.060 |
Why?
|
Lipids | 3 | 2005 | 3344 | 0.060 |
Why?
|
Visual Acuity | 1 | 2015 | 2714 | 0.060 |
Why?
|
Thiourea | 1 | 2005 | 68 | 0.060 |
Why?
|
Physician Assistants | 1 | 2007 | 190 | 0.060 |
Why?
|
Albuminuria | 1 | 2009 | 658 | 0.060 |
Why?
|
Dextrans | 2 | 1999 | 574 | 0.060 |
Why?
|
Hydrocortisone | 5 | 1999 | 1841 | 0.060 |
Why?
|
Prospective Studies | 4 | 2015 | 54920 | 0.060 |
Why?
|
Hypokalemia | 1 | 2006 | 153 | 0.060 |
Why?
|
Sodium-Calcium Exchanger | 1 | 2005 | 90 | 0.060 |
Why?
|
Aneurysm | 1 | 2008 | 343 | 0.060 |
Why?
|
Telepathology | 1 | 2005 | 77 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2010 | 964 | 0.060 |
Why?
|
Dietary Fats, Unsaturated | 1 | 2005 | 223 | 0.060 |
Why?
|
Circadian Rhythm | 5 | 2005 | 2588 | 0.060 |
Why?
|
Nurse Practitioners | 1 | 2007 | 271 | 0.060 |
Why?
|
Dietary Carbohydrates | 2 | 2005 | 896 | 0.060 |
Why?
|
Diet Therapy | 1 | 2005 | 150 | 0.060 |
Why?
|
Government Agencies | 1 | 2004 | 161 | 0.060 |
Why?
|
Enalapril | 1 | 2005 | 316 | 0.060 |
Why?
|
Lasers | 1 | 2008 | 952 | 0.050 |
Why?
|
Benzimidazoles | 2 | 2000 | 864 | 0.050 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2005 | 241 | 0.050 |
Why?
|
Dietary Proteins | 2 | 2005 | 960 | 0.050 |
Why?
|
Optic Disk | 1 | 2007 | 422 | 0.050 |
Why?
|
Logistic Models | 2 | 2010 | 13323 | 0.050 |
Why?
|
Medical Staff, Hospital | 1 | 2007 | 603 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 710 | 0.050 |
Why?
|
Safety | 1 | 2007 | 1159 | 0.050 |
Why?
|
Clinical Trials as Topic | 4 | 2005 | 8051 | 0.050 |
Why?
|
Osteocalcin | 2 | 1994 | 277 | 0.050 |
Why?
|
Urology | 1 | 2007 | 411 | 0.050 |
Why?
|
Immediate-Early Proteins | 1 | 2005 | 444 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3627 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 3 | 1999 | 619 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2005 | 752 | 0.050 |
Why?
|
Amiloride | 2 | 1993 | 116 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2014 | 39407 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14737 | 0.050 |
Why?
|
Insulin Infusion Systems | 1 | 2023 | 221 | 0.050 |
Why?
|
Retinal Diseases | 1 | 2008 | 710 | 0.050 |
Why?
|
Disease Management | 1 | 2012 | 2537 | 0.050 |
Why?
|
Models, Economic | 1 | 2005 | 718 | 0.050 |
Why?
|
Health Services | 1 | 2006 | 756 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2010 | 2742 | 0.050 |
Why?
|
Calcium Gluconate | 3 | 1999 | 22 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2024 | 794 | 0.040 |
Why?
|
Phenotype | 3 | 2010 | 16721 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2015 | 20224 | 0.040 |
Why?
|
Program Development | 1 | 2006 | 1298 | 0.040 |
Why?
|
Plasma Substitutes | 1 | 1999 | 58 | 0.040 |
Why?
|
Awards and Prizes | 1 | 2024 | 365 | 0.040 |
Why?
|
Risk Factors | 8 | 2013 | 74962 | 0.040 |
Why?
|
Enzyme Activation | 2 | 1998 | 3587 | 0.040 |
Why?
|
Adrenal Cortex | 1 | 1999 | 134 | 0.040 |
Why?
|
Ophthalmology | 1 | 2005 | 560 | 0.040 |
Why?
|
Citric Acid | 3 | 1994 | 124 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2005 | 12456 | 0.040 |
Why?
|
Alleles | 1 | 2010 | 6892 | 0.040 |
Why?
|
Policy | 1 | 2023 | 514 | 0.040 |
Why?
|
Medical Errors | 1 | 2007 | 1263 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3858 | 0.040 |
Why?
|
Diet, Fat-Restricted | 3 | 2009 | 329 | 0.040 |
Why?
|
Heart Diseases | 2 | 2005 | 2819 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15455 | 0.040 |
Why?
|
Reference Values | 4 | 1996 | 4941 | 0.040 |
Why?
|
Mibefradil | 1 | 1998 | 5 | 0.040 |
Why?
|
Valine | 1 | 2000 | 410 | 0.040 |
Why?
|
Program Evaluation | 1 | 2007 | 2505 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2005 | 1118 | 0.040 |
Why?
|
Dihydropyridines | 1 | 1998 | 67 | 0.040 |
Why?
|
Electrocardiography | 3 | 2007 | 6409 | 0.040 |
Why?
|
Housing | 1 | 2023 | 680 | 0.040 |
Why?
|
Cardiovascular Diseases | 5 | 2013 | 15649 | 0.040 |
Why?
|
Glaucoma | 1 | 2007 | 1194 | 0.040 |
Why?
|
Hypercholesterolemia | 1 | 2005 | 1142 | 0.040 |
Why?
|
Cells, Cultured | 5 | 2005 | 19022 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2002 | 279 | 0.040 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2005 | 1658 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2010 | 18048 | 0.040 |
Why?
|
Tetrahydronaphthalenes | 1 | 1998 | 86 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1669 | 0.040 |
Why?
|
Biological Transport | 1 | 2002 | 2085 | 0.040 |
Why?
|
Sodium Chloride | 1 | 1999 | 584 | 0.040 |
Why?
|
Verapamil | 1 | 1998 | 242 | 0.040 |
Why?
|
Uric Acid | 1 | 2023 | 806 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 1998 | 326 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2005 | 2003 | 0.030 |
Why?
|
Students, Medical | 2 | 2007 | 1964 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2010 | 3267 | 0.030 |
Why?
|
Weight Loss | 1 | 2008 | 2713 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6318 | 0.030 |
Why?
|
Feeding Behavior | 1 | 2009 | 3203 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2002 | 997 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2005 | 2398 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2002 | 1397 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 1999 | 657 | 0.030 |
Why?
|
Drug Interactions | 1 | 2000 | 1420 | 0.030 |
Why?
|
Fasting | 1 | 2002 | 1610 | 0.030 |
Why?
|
Erythrocyte Membrane | 1 | 1997 | 438 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2002 | 10776 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2016 | 11516 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2000 | 1026 | 0.030 |
Why?
|
Linear Models | 2 | 2001 | 5878 | 0.030 |
Why?
|
Military Personnel | 1 | 2004 | 1266 | 0.030 |
Why?
|
Elasticity | 2 | 2007 | 657 | 0.030 |
Why?
|
Animals | 8 | 2007 | 169337 | 0.030 |
Why?
|
Analysis of Variance | 2 | 1993 | 6241 | 0.030 |
Why?
|
Research Design | 2 | 2014 | 6210 | 0.030 |
Why?
|
Clinical Protocols | 2 | 2014 | 1445 | 0.030 |
Why?
|
Fibroblasts | 1 | 2005 | 4177 | 0.030 |
Why?
|
p-Aminohippuric Acid | 1 | 1993 | 36 | 0.030 |
Why?
|
Retina | 1 | 2005 | 2661 | 0.030 |
Why?
|
Tetrazoles | 1 | 2000 | 923 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9742 | 0.030 |
Why?
|
Rats | 2 | 2005 | 23835 | 0.030 |
Why?
|
Pyridines | 1 | 2005 | 2889 | 0.030 |
Why?
|
Cell Membrane | 2 | 2005 | 3663 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 1998 | 990 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2022 | 1133 | 0.030 |
Why?
|
Health Promotion | 2 | 2023 | 2209 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13646 | 0.030 |
Why?
|
Hypoaldosteronism | 1 | 1992 | 7 | 0.030 |
Why?
|
Dopamine | 2 | 1990 | 1617 | 0.030 |
Why?
|
Boston | 1 | 2005 | 9371 | 0.020 |
Why?
|
Carotid Arteries | 2 | 2007 | 943 | 0.020 |
Why?
|
Hematocrit | 1 | 1993 | 625 | 0.020 |
Why?
|
Phorbol 12,13-Dibutyrate | 1 | 1991 | 40 | 0.020 |
Why?
|
Myocardium | 1 | 2005 | 4788 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2005 | 12805 | 0.020 |
Why?
|
C-Peptide | 1 | 2013 | 443 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2303 | 0.020 |
Why?
|
Sodium Radioisotopes | 1 | 1990 | 6 | 0.020 |
Why?
|
Clinical Competence | 1 | 2006 | 4848 | 0.020 |
Why?
|
Minority Groups | 1 | 1998 | 1215 | 0.020 |
Why?
|
Fluoresceins | 1 | 1990 | 235 | 0.020 |
Why?
|
Norepinephrine | 1 | 1992 | 900 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2013 | 1183 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 1989 | 862 | 0.020 |
Why?
|
Biomedical Research | 1 | 2024 | 3464 | 0.020 |
Why?
|
Blotting, Northern | 2 | 2005 | 1553 | 0.020 |
Why?
|
Natriuresis | 2 | 2003 | 105 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 9063 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3960 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 2005 | 1727 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2008 | 26375 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1117 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2011 | 22296 | 0.020 |
Why?
|
Vitreous Body | 1 | 2008 | 400 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2005 | 18362 | 0.020 |
Why?
|
Fats, Unsaturated | 1 | 2005 | 21 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 2465 | 0.020 |
Why?
|
Connective Tissue Growth Factor | 1 | 2005 | 91 | 0.010 |
Why?
|
Pamphlets | 1 | 2005 | 71 | 0.010 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 2005 | 190 | 0.010 |
Why?
|
Pulsatile Flow | 1 | 2005 | 320 | 0.010 |
Why?
|
Glaucoma, Open-Angle | 1 | 2011 | 742 | 0.010 |
Why?
|
Public Health | 1 | 1998 | 2682 | 0.010 |
Why?
|
NF-kappa B | 1 | 2013 | 2489 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2007 | 1502 | 0.010 |
Why?
|
Edetic Acid | 2 | 1999 | 278 | 0.010 |
Why?
|
Young Adult | 1 | 2011 | 60049 | 0.010 |
Why?
|
Risk Management | 1 | 2007 | 558 | 0.010 |
Why?
|
Femoral Artery | 1 | 2007 | 829 | 0.010 |
Why?
|
Luciferases | 1 | 2005 | 712 | 0.010 |
Why?
|
Tissue Plasminogen Activator | 2 | 2002 | 1163 | 0.010 |
Why?
|
Adolescent | 1 | 2011 | 89184 | 0.010 |
Why?
|
Age Factors | 2 | 2014 | 18471 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 1990 | 1926 | 0.010 |
Why?
|
Retinal Vessels | 1 | 2008 | 864 | 0.010 |
Why?
|
Heart Failure | 1 | 2006 | 11858 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2005 | 1585 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1992 | 8199 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1998 | 14784 | 0.010 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2005 | 637 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2013 | 3334 | 0.010 |
Why?
|
Health Facilities | 1 | 2005 | 577 | 0.010 |
Why?
|
Phosphorylation | 2 | 2005 | 8326 | 0.010 |
Why?
|
Schools, Medical | 1 | 2007 | 881 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2005 | 1261 | 0.010 |
Why?
|
Metoclopramide | 2 | 1990 | 51 | 0.010 |
Why?
|
Educational Measurement | 1 | 2007 | 1256 | 0.010 |
Why?
|
Microcirculation | 1 | 2005 | 1282 | 0.010 |
Why?
|
Osteoblasts | 1 | 2005 | 1154 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2009 | 2103 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4588 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2009 | 2906 | 0.010 |
Why?
|
Learning | 1 | 2007 | 1761 | 0.010 |
Why?
|
Sex Factors | 2 | 2001 | 10654 | 0.010 |
Why?
|
Dietary Fats | 1 | 2005 | 2003 | 0.010 |
Why?
|
Phosphoserine | 1 | 1997 | 204 | 0.010 |
Why?
|
Models, Biological | 1 | 1993 | 9493 | 0.010 |
Why?
|
Collagen | 1 | 2005 | 2646 | 0.010 |
Why?
|
RNA | 1 | 2005 | 2726 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2708 | 0.010 |
Why?
|
Cholesterol | 1 | 2004 | 2912 | 0.010 |
Why?
|
Lithium | 1 | 1997 | 600 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2004 | 2181 | 0.010 |
Why?
|
Child | 1 | 2022 | 80891 | 0.010 |
Why?
|
Massachusetts | 1 | 2006 | 8902 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 13052 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5099 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10863 | 0.010 |
Why?
|
Echocardiography | 1 | 2005 | 5044 | 0.010 |
Why?
|
Risk | 1 | 2005 | 9636 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2005 | 5538 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9343 | 0.010 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 1992 | 99 | 0.010 |
Why?
|
Dexamethasone | 1 | 1999 | 1965 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15597 | 0.010 |
Why?
|
Coronary Thrombosis | 1 | 1993 | 440 | 0.010 |
Why?
|
Glucocorticoids | 1 | 1999 | 2168 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 1988 | 363 | 0.000 |
Why?
|
Motivation | 1 | 1998 | 2029 | 0.000 |
Why?
|
Electrolytes | 1 | 1988 | 278 | 0.000 |
Why?
|
Delivery of Health Care | 1 | 2005 | 5375 | 0.000 |
Why?
|
Glucose | 1 | 1999 | 4352 | 0.000 |
Why?
|
Signal Transduction | 1 | 2005 | 23631 | 0.000 |
Why?
|
Drug Administration Schedule | 1 | 1989 | 4859 | 0.000 |
Why?
|
Membrane Proteins | 1 | 1997 | 7880 | 0.000 |
Why?
|
Vitamin D | 1 | 1988 | 3310 | 0.000 |
Why?
|